Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  SHANGHAI STOCK EXCHANGE  >  Tasly Pharmaceutical Group Co Ltd    600535   CNE000001C81

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Tasly Pharmaceutical Group Co Ltd : CEO Bill Dai Visits Myanmar (2013-04-10)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/12/2013 | 12:02am CEST

Tasly Pharmaceutical International CEO Bill Dai made a 3-day visit to the Myanmarese market from 24 to 26 March 2013 in the company of the management of the South Asian division, and Ms. Kung and Mr. Wang Zhongyuan, reps of a Myanmarese partner.

CEO Bill Dai Talking with Myanmarese Traditional Medicine Officials

CEO Bill Dai Meeting with U Thurein Zaw, Member of the Assembly of the Union and Chairman of State Budget Commission

The CEO, during his 45-hour stay, took a 10-hour ride to shuttle between Yangon and the new capital Naypyidaw, meeting U Win Myint, head of the Department of Traditional Medicine, the Ministry of Health, and U Thurein Zaw, member of the Assembly of the Union and chairman of State Financial Budget Commission of Myanmar, and attending a business invitation meeting hosted by the Myanmarese partner. The speeches of the CEO inspired enthusiastic responses from the attendees, deepened the understanding and knowledge of both the local government and people on Tasly Group, increased the recognition and trust of local government agencies in the Tasly brand, and boosted the consumers' confidence in and passion for Tasly products.

During talks with officials from the Department of Traditional Medicine, CEO Dai negotiated with them on Tasly helping the Department understand the GMP system, establish GMP certification criteria and build GMP-compliant plants. The talks were finally concluded with the CEO's warmly inviting the officials to Tasly headquarters for visits and technical exchanges.

At the meeting with U Thurein Zaw, member of the Assembly of the Union and chairman of State Financial Budget Commission of Myanmar, the two exchanged views on topics like Myanmar's political system, economic development, Sino-Myanmarese friendship and water conservancy. U Thurein Zaw expressed his hope for everlasting friendship between the two nations and for Tasly's investment in Myanmar. The chairman, who is also a loyal user of Tasly products, said that he would be very happy to recommend Tasly products to more friends as a result of the strong effects of iCP and Deepure that he had been using.

Ms. Kung remarked in her speech: "CEO Dai not only brings health and the fruits of Tasly's studies in modernized TCM to the people here but erects a bridge of hope for the cooperation and communication of China and Myanmar in TCM."

This "Branding & Bridging" trip of the CEO to Myanmar created a new situation for the international marketing of Tasly, which, by grasping this opportunity, will definitely boost the prospects of its Pan-health cause in the country.

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on TASLY PHARMACEUTICAL GROUP
09/04 TASLY PHARMACEUTICAL : VP Receives Attendees of High-level Workshop
07/20 TASLY PHARMACEUTICAL : Leaders from BRICS Ministry of Health Visited Tasly
06/07 TASLY PHARMACEUTICAL : Minister-counselor of Embassy of South America in Beijing..
05/10 TASLY PHARMACEUTICAL : Takes Stake in French Biomedicine Maker
04/17 TASLY PHARMACEUTICAL : Q1 Profit Up 15%
2016 TASLY PHARMACEUTICAL : won Top 20 of Most Competitive Pharmaceutical Listed Comp..
2016 TASLY PHARMACEUTICAL : listed in Top 100 of Chinese Pharmaceutical Industry in 2..
2016 TASLY PHARMACEUTICAL : Breakthrough in TCM Smart Manufacture Technology (2016-07..
2016 TASLY PHARMACEUTICAL : 2016 Shareholders’ Committee, Board of Directors, a..
2016 TASLY PHARMACEUTICAL : The Announcement of FDAⅢ Progress of Dantonic Pill ..
More news
Financials ( CNY)
Sales 2017 15 610 M
EBIT 2017 1 989 M
Net income 2017 1 397 M
Debt 2017 3 286 M
Yield 2017 1,61%
P/E ratio 2017 27,07
P/E ratio 2018 22,93
EV / Sales 2017 2,71x
EV / Sales 2018 2,38x
Capitalization 39 048 M
Chart TASLY PHARMACEUTICAL GROUP
Duration : Period :
Tasly Pharmaceutical Group Technical Analysis Chart | 600535 | CNE000001C81 | 4-Traders
Technical analysis trends TASLY PHARMACEUTICAL GROUP
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Average target price 44,6  CNY
Spread / Average Target 23%
EPS Revisions
Managers
NameTitle
Yong Hong Zhu General Manager & Director
Jian Zhong Zhang Chairman-Supervisory Board
Kai Jing Yan Chairman
Rui Hua Wang Chief Financial Officer
Xi Jun Yan Director
Sector and Competitors
1st jan.Capitalization (M$)
TASLY PHARMACEUTICAL GROUP CO LTD-12.89%5 936
JOHNSON & JOHNSON18.42%366 178
NOVARTIS13.23%225 160
ROCHE HOLDING LTD.5.20%216 764
PFIZER11.88%216 409
MERCK AND COMPANY7.68%172 887